Medicare Prior Auth Still Blocks Lifesaving Drugs

Hospitalization After Prior Auth Denial Puts Industry Promises in Focus

A Missouri woman's struggle to obtain a medication her immune system depends on — ending in a hospital stay — spotlights continuing problems with prior authorization in Medicare Advantage plans, according to a June 29, 2026 report from KFF Health News.

Margaret Hvatum's insurer denied coverage of the immune-boosting drug she relies on, and the resulting entanglement in the preapproval process left her without the medication long enough to require hospitalization, KFF Health News reported. The case has drawn attention in part because major insurers have publicly pledged to improve the prior authorization process — yet stories like Hvatum's suggest those improvements have not consistently reached individual patients.

What Prior Authorization Is — and Why It Keeps Generating Controversy

Prior authorization — sometimes called prior auth or preapproval — is a process used by Medicare Advantage (Part C) plans and many Part D drug plans that requires physicians to obtain insurer approval before certain treatments or medications are covered. Insurers say the process prevents unnecessary care and controls costs. Patient advocates and physicians counter that delays and denials can interrupt medically necessary treatment, sometimes with serious consequences.

The tension is not new, but it has intensified as Medicare Advantage enrollment has grown. Today, more than half of all Medicare beneficiaries are enrolled in a Medicare Advantage plan rather than Original Medicare. Because Original Medicare does not use prior authorization in the same way, the coverage experience can differ significantly depending on which type of plan a beneficiary holds.

In recent years, both Congress and the Centers for Medicare & Medicaid Services (CMS) have taken steps to address prior authorization concerns. CMS rules require Medicare Advantage plans to respond to urgent prior authorization requests within 72 hours and routine requests within seven calendar days. Separately, the insurance industry has made voluntary commitments to reduce inappropriate denials, speed up the review process, and improve transparency around authorization criteria.

When Policy Commitments Don't Match Patient Experience

Hvatum's case, as reported by KFF Health News, illustrates a gap that patient advocates have long warned about: the distance between high-level policy commitments and the day-to-day experience of individual enrollees. Even when regulations and voluntary pledges are in place, the prior authorization process can still create harmful delays — particularly for complex or specialty medications that require detailed documentation, physician letters, or multiple rounds of review.

Immune-system drugs, biologics, and specialty therapies are among the categories most commonly subject to prior authorization and most likely to face delays. These are also medications where interruptions in therapy can carry real health risks, as Hvatum's hospitalization illustrates.

KFF Health News did not report a finding of wrongdoing or a specific regulatory violation in Hvatum's case. What the reporting demonstrates is systemic risk: patients with legitimate medical need and physician support can still become caught in administrative processes that are difficult to navigate, especially when they are already managing a serious health condition. The story is part of KFF's ongoing Bill of the Month series documenting real-world insurance and billing problems faced by American patients.

Steps Medicare Beneficiaries Can Take Now

The Hvatum case is a practical prompt for any Medicare enrollee who depends on ongoing medication. A few proactive steps can reduce the risk of a similar disruption:

• Check your drug's status. Review your plan's formulary — available on the plan's website or in your Evidence of Coverage — to see whether your medications require prior authorization, step therapy, or quantity limits.
• Know your appeal rights. Medicare Advantage enrollees have the right to appeal a prior authorization denial. Urgent appeals must be decided within 72 hours; standard appeals within 30 days. Your doctor can also request a peer-to-peer review — a direct conversation with the insurer's medical reviewer — which sometimes leads to a reversal of the initial decision.
• Document every interaction. Keep records of prior authorization requests, denial notices, and communications with your insurer, including dates and reference numbers. This documentation matters if you need to escalate to a formal appeal or file a complaint with CMS.
• Contact your State Health Insurance Assistance Program (SHIP). SHIP counselors provide free, unbiased help navigating Medicare coverage problems, including prior authorization disputes. Find your local SHIP at shiphelp.org.

For people approaching Medicare enrollment who are weighing Original Medicare against Medicare Advantage, prior authorization is a meaningful factor to consider — particularly if you take specialty or biologic medications. Original Medicare generally does not require preapproval for covered services in the same way Advantage plans do, though it comes with different cost structures and coverage tradeoffs. A licensed insurance agent or SHIP counselor can help you compare options based on your specific prescriptions and health needs. Stories like Hvatum's are a useful reminder to review your current plan's rules before a prior authorization dispute becomes a medical emergency.